Status: Recruiting
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase (MP). Part B (open-label extension, OLE) is an open-label, 11-month extension study carried out in participants who come from Part A and meet certain inclusion criteria.
Participants needed: 420
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Waterstone Pharmaceutical (Wuhan) Co., LTD.Updated: Nov 26, 2025Locations: 50
Eligibility criteria
Adults (male or female) aged 18 years and older; [+3]
Participants who have a history of severe drug allergy, or are definitely allerg... [+11]